Pronab Sensarma, MD
Cardiovascular Disease · Wichita, KSNPI 1073595815
Payments from drug & device makers
Across 148 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$478
- AstraZeneca$445
- Novartis$240
- Abbott$195
- Merck$163
- Johnson & Johnson$142
- plus $979 from 23 others
What the payments were for
- Travel & lodging$351%
- Food & beverage$2,52596%
- Education$592%
- Entertainment$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 13 | $478 |
| AstraZeneca | 30 | $445 |
| Novartis | 16 | $240 |
| Abbott | 11 | $195 |
| Merck | 11 | $163 |
| Johnson & Johnson | 10 | $142 |
| United Therapeutics Corporation | 8 | $126 |
| Boehringer Ingelheim | 6 | $82 |
| Boston Scientific | 4 | $75 |
| Amgen | 5 | $67 |
| Cvrx, Inc. | 1 | $65 |
| Biotronik Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Pfizer | 4 | $54 |
| Abiomed | 1 | $41 |
| Terumo Medical Corporation | 1 | $35 |
| Bardy Diagnostics, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Gilead | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Philips North America LLC | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Sanofi | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Canon Medical Systems USA, Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,643 in reported general payments places this provider in the 45th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FenofibrateFenofibrate Nanocrystallized | 13 | $332 |
| Metoprolol Succinate | 25 | $170 |
| SotalolSotalol Hcl | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Thomas AshcomWichita$193K
- Joseph GalichiaWichita$177K
- Layne ReusserWichita$91K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.